Skip to content Skip to sidebar Skip to footer

Newsletter

Life Sciences

PYC Therapeutics (ASX:PYC): Its been raising ~$650m to fund 4 clinical assets for multiple years!

PYC Therapeutics (ASX:PYC) is currently in the Top 25 ASX healthcare stocks and is the 4th largest biotech, only trailing Telix, Mesoblast and Neuren. Clearly this is one worth looking into and this was before a capital raising that would be $650m and purportedly fund the company into next decade. What are the Best ASX Life…

ByNick SundichFebruary 5, 2026

Epiminder (ASX:EPI): Less than 2 months since its IPO, this medtech made its first implant

Epiminder (ASX:EPI) only listed on the ASX at the end of November last year, but just announced to market that it completed the first implant of its Minder system in the USA.The company's Minder system is an epilepsy monitoring technology which is in a global clinical trial which will enrol over 200 patients. Shares only…

ByNick SundichJanuary 21, 2026

Ozempic and other GLP-1 Drugs: Here’s Where Things Are Headed in 2026

At Stocks Down Under, it has been a while since we've looked at Ozempic and other GLP-1 Drugs. Investors paid a lot of attention to them in 2023, particularly those invested in companies with potential to be impacted directly or indirectly. The industry has come a fair way in the past couple of years and…

ByNick SundichJanuary 6, 2026

Stocks Down Under’s Top 10 Hottest ASX Stocks to Look At in 2026!

Today, on the first trading day of 2026, Stocks Down Under publishes its its 10 Hottest ASX Stocks to Look At in the year ahead! What are the Best ASX Stocks to invest in right now? Check our buy/sell tips[sg_popup id="23914" event="click"][/sg_popup] Stocks Down Under's Top 10 Hottest ASX Stocks to Look At in 2026! Note: These…

ByNick SundichJanuary 2, 2026

Our 5 ASX Predictions for 2026!

This article outlines 5 ASX Predictions for 2026 that Stocks Down Under puts its neck on the line to assert will happen. It has become an annual tradition of ours, and some of these calls we get right, others we don't. Arguably our boldest call in suggesting ANZ would be the best performing big 4…

ByNick SundichDecember 24, 2025

Vertex Pharmaceuticals (NDQ:VRTX): Another >US$100bn biotech that is facing the cliff like its peers, but might be safer

$100bn biotechs like Vertex Pharmaceuticals (NDQ:VRTX) typically get to their position through 'blockbuster drugs' with periods of market exclusivity, which eventually come to an end and cause revenues to fall as cheaper biosimilars come onto the market. The average biotech is facing a loss of revenue of 38%. Of course, some are higher (i.e. Amgen…

ByNick SundichOctober 23, 2025

Pfizer (NYSE:PFE) shares are still declining post-pandemic! Does the company have a future?

The dream run Pfizer had during the pandemic was not going to last forever. But while certain companies that derived a windfall during the pandemic (one example being Sonic (ASX:SHL)) had decent businesses pre-COVID and began to 'normalise' post-pandemic, Pfizer has continued to decline (shares have dropped another 12% in 2025). What are the Best ASX…

ByNick SundichOctober 13, 2025

PainChek (ASX:PCK): Investors dreamed 2025 would be the year it finally enters the US market, and their dreams are becoming a reality!

PainChek (ASX:PCK) has among the most admirable medical technologies there is, in the form of an app that can detect pain in non-verbal patients.Unfortunately, there has been pain for investors along the way. When it was announced that it was participating in a clinical trial the Morrison government was investing $5m in back in 2019,…

ByNick SundichOctober 8, 2025

Cyclopharm (ASX:CYC): FDA approved for 2 years now, but a lawsuit from 4DX is the latest headache and cause for investor scepticism

Cyclopharm (ASX:CYC) is a rare species - an ASX stock that is approved in the US market. However, its share price has gone in the opposite direction. Cyclopharm has not had as fast an uplift as other companies have had and still makes most of its sales from other jurisdictions. A lawsuit from 4D Medical…

ByNick SundichOctober 8, 2025

Activist investors: Here’s what you need to know about them and 4 famous Australian activists to watch out for

Hear the term 'Activist investors' and you might think of GetUp, the progressive activist group that forced Woolworths to hold an EGM in 2014 in an attempt to limit the maximum bets on poker machines to $1. Or perhaps even of ESG-focused fundies like Australian Ethical (ASX:AEF). The reality is a lot more complicated and…

ByNick SundichOctober 8, 2025

the Kick-ass Multipurpose WordPress Theme

Life Sciences

PYC Therapeutics (ASX:PYC): Its been raising ~$650m to fund 4 clinical assets for multiple years!

Epiminder (ASX:EPI): Less than 2 months since its IPO, this medtech made its first implant

Ozempic and other GLP-1 Drugs: Here’s Where Things Are Headed in 2026

Stocks Down Under’s Top 10 Hottest ASX Stocks to Look At in 2026!

Our 5 ASX Predictions for 2026!

Vertex Pharmaceuticals (NDQ:VRTX): Another >US$100bn biotech that is facing the cliff like its peers, but might be safer

Pfizer (NYSE:PFE) shares are still declining post-pandemic! Does the company have a future?

PainChek (ASX:PCK): Investors dreamed 2025 would be the year it finally enters the US market, and their dreams are becoming a reality!

Cyclopharm (ASX:CYC): FDA approved for 2 years now, but a lawsuit from 4DX is the latest headache and cause for investor scepticism

Activist investors: Here’s what you need to know about them and 4 famous Australian activists to watch out for

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Life Sciences

Stocks in Spotlight

Add Your Heading Text Here